Heart disease is the world's #1 leading cause of death ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from HeartSciences.
Since heart disease is the world's #1 leading cause of death, it's no surprise when an AI company working to solve it gets a "Strong Buy" rating from some analysts – and a 270% 1-year growth target. 
For decades, millions with heart disease have gone undiagnosed because effective heart diagnostics are expensive and require cardiologists. But HeartSciences (Nasdaq: HSCS) is helping bridge that gap. Their AI-ECG, developed with Mount Sinai, brings specialist-grade insights to routine frontline exams so issues will be caught faster and more affordably by frontline doctors. And they're hitting several major milestones as we speak: - First commercial customer for their software platform, a cardiology center providing services to the UK's NHS, one of the largest healthcare networks in the world
- FDA Breakthrough Device Designation, providing priority review and a faster path to market
- New foundational U.S. patent issued, bringing the total to 44 granted patents and further protecting their AI-ECG technology from competitors
- FDA submission for their device expected in 2025
While HeartSciences is already public, they're giving investors an opportunity not available on the public exchange: $3.50 units that include 1 warrant + 1 share of preferred stock convertible to common at any time. Learn More and Invest in HeartSciences
Disclosures This is a paid advertisement for HeartSciences Regulation A+ offering
Please read the offering circular at invest.heartsciences.com |
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of HeartSciences (Nasdaq: HSCS). The compensation consists of up to $4,000 and was received/will be received from Investing Media Solutions. This communication should not be considered as an endorsement of the securities of adviser HeartSciences (Nasdaq: HSCS) and we are not responsible for any errors or omissions in any information provided about the securities of HeartSciences (Nasdaq: HSCS) by Investing Media Solutions. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 08/19/2025.
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
Behind the Markets
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.
|
|
No comments:
Post a Comment